Sirolimus-Eluting and Paclitaxel-Eluting Stents for Coronary Revascularization

2005591 citationsJournal Article

Authors

Stephan Windecker · University Hospital of Bern

Andréa Remondino · University Hospital of Bern

Franz R. Eberli · University Hospital of Zurich

Peter Jüni · Institute of Social and Preventive Medicine

Lorenz Räber · University Hospital of Bern

Peter Wenaweser · University Hospital of Bern

Mario Togni

Abstract

As compared with paclitaxel-eluting stents, the use of sirolimus-eluting stents results in fewer major adverse cardiac events, primarily by decreasing the rates of clinical and angiographic restenosis.

Topics & Keywords

Coronary Interventions and Diagnostics Cardiac Valve Diseases and Treatments Antiplatelet Therapy and Cardiovascular Diseases

UN Sustainable Development Goals

Good health and well-being

Publication Details

Published in: New England Journal of Medicine

Volume 353, Issue 7, pp. 653-662

DOI: 10.1056/nejmoa051175

Field-Weighted Citation Impact: 71.64